'Goldmine' U.K. study may hint why Israel has had a larger issue with waning vaccine protection

A "goldmine" of data published by Public Health England on Tuesday provides a look at who may need COVID-19 booster shots, the Financial Times' John Burn-Murdoch reports.
Breaking down the numbers in a series of charts, Burn-Murdoch explains that both the Pfizer-BioNTech and AstraZeneca vaccines, which are the predominant shots in the United Kingdom, have generally held up well against symptomatic coronavirus infections, hospitalizations, and deaths even as the Delta variant took over. There are indications of waning immunity over time, though the declines are more significant among older people and especially older people with underlying health conditions.
That left Burn-Murdoch with two major takeaways. The study simultaneously suggests that "not everyone needs a booster" and that an extra dose "could make a big difference" for those with comorbidities.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
That idea seems to contrast with what's happening in Israel. The country is encouraging everyone regardless of additional factors, to get a third dose of the Pfizer vaccine (and they're even preparing for the possibility of a fourth) because of more drastic signs of waning immunity. But Burn-Murdoch argues the new data backs up the theory that a longer interval between doses deployed by the U.K. sets the stage for better long-term protection than the shorter break taken by Israel and the United States.
The good news is that Israel's booster campaign is working well, so it's worth keeping an eye on what that says about maximizing vaccine efficacy going forward.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
A whole new world: redrawing the Mercator map
Under the Radar African Union joins calls to ditch 'colonial distortion' and portray countries at more accurate size
-
'Enforcement of rulings remains spotty at best'
Instant Opinion Opinion, comment and editorials of the day
-
Book reviews: 'King of Kings: The Iranian Revolution' and 'Gwyneth: The Biography'
Feature How the Iranian Revolution began and Gwyneth Paltrow's life in the spotlight
-
Texas declares end to measles outbreak
Speed Read The vaccine-preventable disease is still spreading in neighboring states, Mexico and Canada
-
RFK Jr. shuts down mRNA vaccine funding at agency
Speed Read The decision canceled or modified 22 projects, primarily for work on vaccines and therapeutics for respiratory viruses
-
Cytomegalovirus can cause permanent birth defects
The Explainer The virus can show no symptoms in adults
-
Measles cases surge to 33-year high
Speed Read The infection was declared eliminated from the US in 2000 but has seen a resurgence amid vaccine hesitancy
-
Kennedy's vaccine panel signals skepticism, change
Speed Read RFK Jr.'s new vaccine advisory board intends to make changes to the decades-old US immunization system
-
Kennedy ousts entire CDC vaccine advisory panel
speed read Health Secretary RFK Jr. is a longtime anti-vaccine activist who has criticized the panel of experts
-
RFK Jr. scraps Covid shots for pregnant women, kids
Speed Read The Health Secretary announced a policy change without informing CDC officials
-
New FDA chiefs limit Covid-19 shots to elderly, sick
speed read The FDA set stricter approval standards for booster shots